Korean J Dermatol.  2016 Nov;54(9):739-743.

Bortezomib-induced Histiocytoid Sweet Syndrome

Affiliations
  • 1Department of Dermatology, College of Medicine, Kyung Hee University, Seoul, Korea. bellotte@hanmail.net

Abstract

Sweet syndrome is an acute febrile neutrophilic dermatosis predominantly characterized by fever, an elevated neutrophil count, and erythematous skin lesions comprising plaques and nodules that mainly appear on the upper extremities, face, and neck. The incidence of Sweet syndrome in the general population is unknown because of limited reports on this condition. Bortezomib, an antineoplastic agent that is the standard of care for multiple myeloma, has been reported to be associated with Sweet syndrome. We describe the case of a 66-year-old man who developed bortezomib-induced histiocytoid Sweet syndrome during treatment for multiple myeloma.

Keyword

Bortezomib; Sweet syndrome

MeSH Terms

Aged
Bortezomib
Fever
Humans
Incidence
Multiple Myeloma
Neck
Neutrophils
Skin
Standard of Care
Sweet Syndrome*
Upper Extremity
Bortezomib
Full Text Links
  • KJD
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2022 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr